An unusual cause of cancer mimicry following liver transplantation
Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR). As sirolimus functions through a pathway independent of calcineurin inhibition, it may have less potential for nephrotoxicity and carcino...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-01-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S166526811931498X |